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In order to investigate the relationship between chromosomal radiosensitivity and early-onset cancer, the G2 chromosomal
radiosensitivity assay was undertaken on a group of 23 Danish survivors of childhood and adolescent cancer, a control group
comprising their partners and a group of 38 of their offspring. In addition, the previously reported in-house control group from
Westlakes Research Institute (WRI) was extended to 27 individuals. When using the 90th percentile cutoff for the WRI control
group, the proportion of individuals with elevated radiosensitivity was 11, 35, 52 and 53% for the WRI control, partner control,
cancer survivor and the offspring groups, respectively, with significant differences between the WRI control group and the cancer
survivor group (P¼0.002) and the offspring group (Po0.001). However, while the comparisons with the WRI control group support
an association of chromosomal radiosensitivity with cancer predisposition, when the partner control group was used to define the
radiosensitivity cutoff point, no significant differences in radiosensitivity profiles were found between the partner control group and
either the cancer survivor group or the offspring group. The failure to distinguish between the G2 aberration profiles of the apparently
normal group of partners and the cancer survivor group suggests that any association with cancer should be viewed with caution, but
also raises questions as to the suitability of the partners of cancer survivors to act as an appropriate control group. Heritability of the
radiosensitive phenotype was examined by segregation analysis of the Danish families and suggested that 67.3% of the phenotypic
variance of G2 chromosomal radiosensitivity is attributable to a putative major gene locus with dominant effect.
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The association between chromosomal radiosensitivity and
increased susceptibility to cancer has been demonstrated for a
number of cancer-prone heritable conditions, most notably ataxia
telangiectasia (Parshad and Sanford, 2001). The cell-cycle-based G2
radiosensitivity assay gives the best discrimination and involves
irradiating cells in vitro during the G2 stage of the cell cycle and
observing unrepaired damage, in the form of chromatid breaks
and gaps, at the subsequent metaphase. The assay was first
developed using fibroblasts (Sanford et al, 1989) and subsequently
applied to lymphocytes (Scott et al, 1996). In addition to the rare
well-defined cancer susceptibility syndromes, enhanced G2 chro-
mosomal radiosensitivity has been demonstrated in a high
proportion of unselected breast cancer patients (Scott et al, 1994,
1999; Parshad et al, 1996; Patel et al, 1997; Riches et al, 2001), a
group of breast cancer patients with a known family history of the
disease (Baeyens et al, 2002) and a heterogeneous group of adult
cancer patients (Terzoudi et al, 2000). This led to the suggestion
that G2 radiosensitivity could be a marker of cancer predisposing
genes of low penetrance (Scott et al, 1999). Further support for this
hypothesis came from a study of first-degree relatives of those with
breast cancer, which demonstrated Mendelian heritability of the
chromosomal radiosensitivity phenotype (Roberts et al, 1999;
Scott, 2000). In addition, the proportion of adults showing
increased G2 chromosomal radiosensitivity has been shown to be
higher among those with cancers having an inherited component,
such as colon cancer, compared to those with cancers with a
predominantly environmental aetiology, such as cervical cancer
(Baria et al, 2001). In a study of head and neck cancer patients,
evidence of increased G2 chromosomal radiosensitivity was
observed in young patients, thus indicating a genetic contribution
to risk for early-onset cases, whereas for older patients, the
proportion exhibiting enhanced sensitivity was the same as that for
a normal healthy control group (Papworth et al, 2001). Using a
slightly different technique, chromosomal radiosensitivity has also
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sbeen reported for patients with glioma and it was suggested that
the apparent broad association of mutagen sensitivity with diverse
cancers indicates that multiple genes in various DNA repair
pathways may be contributing to the integrated phenotype (Bondy
et al, 2001). Baria et al (2002) tested the relationship between
chromosomal radiosensitivity and early-onset cancer in a pilot
study of patients diagnosed before the age of 20 years and found
that 44% of the young cancer patients exhibited increased
chromosomal radiosensitivity compared to 15 and 10% of young
and adult normals, respectively. This led to the suggestion that a
substantial proportion of the patients studied may have a genetic
predisposition to cancer mediated through low penetrance genes
involved with responding to damage to the genome. However, it
was recognised that support for this hypothesis would require the
demonstration of heritability of chromosomal radiosensitivity in
blood relatives of young cancer patients.
In order to further investigate the heritability of chromosomal
radiosensitivity and its relationship with early-onset cancer, we
have performed a pilot study using the G2 assay to examine the
radiosensitivity profile of a group of survivors of childhood and
adolescent cancer and their offspring, with the partners of the
cancer survivors providing a control group for comparison. In
addition, our previously published in-house control group from
Westlakes Research Institute (WRI) in Cumbria, UK (Smart et al,
2003), was extended by the addition of samples from new
individuals.
MATERIALS AND METHODS
Study group
Blood samples were obtained from 28 Danish survivors of
childhood and adolescent cancer (labelled as T01–T28) who had
been treated with radiotherapy, their partners and 44 offspring.
This work forms part of a pilot study for the investigation of a
range of genetic endpoints associated with germ cell mutagenesis
and cancer susceptibility (Boice et al, 2003). These former patients
were selected from the Danish survivor cohort identified from the
files of the nation-wide population-based Danish Cancer Registry.
The Danish survivor cohort consists of 4676 cancer survivors
diagnosed with cancer under 20 years of age between 1943 and
1996 who lived to be at least 15 years of age. Patients included in
the cohort were those alive or born after 1 April 1968 when the
national Central Population Register (CPR) was established with
personal identification numbers for all citizens, thus permitting
linkage among registers. Through linkage to the CPR containing
updated information on vital status, migration and first-degree
relatives, all partners and liveborn children of eligible survivors
were identified. No attempt was made to identify an offspring
control group, nor to distinguish between the sexes, since previous
studies have found no correlation between induced aberration
yields and donor age, or any influence of gender (Baria et al, 2002).
Approval for the study was obtained from the Danish Scientific
Ethical Committee and the Danish Data Protection Agency.
Eligible survivors were contacted by letter to determine their
willingness to participate in the study. The survivors and their
families were invited to the State Hospital, Rigshospitalet,
Copenhagen (for those living in the eastern part of Denmark) or
the Skejby Hospital, Aarhus (for those living in the western part of
Denmark) to complete a short questionnaire and to have blood
drawn. Each of the 28 families who agreed to participate gave
informed consent. Detailed information on cancer type was
abstracted from medical records. To ensure anonymity, each
family was assigned a study number and this was used for all blood
samples and questionnaires. The blood samples were further coded
to avoid identification of cancer survivor, partner and offspring
within each family group. Blood samples were drawn from
participating families on Monday and the samples transported
directly from Copenhagen to WRI by courier, arriving early
Tuesday morning. Samples were hand inspected at customs and, to
ensure they had not been exposed to X-rays, a piece of dental film
was included with each batch. A total of 100 blood samples were
collected and sent to the UK in 10 shipments over 13 months
between March 2002 and April 2003.
Each shipment also contained a blood sample from one healthy
adult Danish volunteer to act as the control for the transportation
system. This volunteer remained the same throughout the study. In
addition, repeat blood samples from one healthy adult WRI
volunteer were obtained in parallel for seven of the shipments to
act as the internal assay control. Some of the samples received at
shipment eight failed to culture successfully and this resulted in
three families (T16–T18) and the associated transport and internal
assay controls being excluded from the study. A further family
(T11) was excluded since offspring samples were not available and
another (T14) because the final diagnosis of the survivor was not
cancer. Thus, only 23 out of the 28 Danish cancer survivor families
proved suitable for analysis, that is, a total of 84 samples, together
with the nine samples from the transport control and the six
samples from the internal assay control. Minisatellite analysis on
four stable loci was undertaken to confirm biological paternity and
maternity for all the offspring samples collected.
In addition to the cancer survivor families, one sample from
each of eight additional healthy control volunteers was taken at
WRI to increase the previously reported WRI control group of 19
individuals (Smart et al, 2003) to 27 individuals, a number more
comparable with that of the cancer survivor group.
The G2 assay
The G2 assay was performed according to the method previously
described by Smart et al (2003), which was based on modified
versions of the work performed by Sanford et al (1989) and Scott
et al (1999). Peripheral blood was drawn into lithium heparin
vacutainers and cultures (2ml blood) were set up in prewarmed
(371C) and pregassed (5% CO2/95% air) RPMI medium supple-
mented with 15% foetal calf serum, 1% L-glutamine and 1%
phytohaemagglutinin (M-form) to a total volume of 20ml. Each
culture was set up in triplicate, one flask for the determination of
the spontaneous aberration frequency and two flasks to be
irradiated for the determination of the induced aberration
frequency. A single foetal calf serum batch was used for the entire
period of the study. Flasks were placed upright in a humidified,
CO2-gassed incubator. After 48h, 15ml of medium was carefully
removed and replaced with 15ml of fresh pregassed, prewarmed
medium. At 72h, the cells were transported in a portable incubator
at 371C and irradiated (or sham irradiated) with 0.5Gy, 300kV X-
rays. Following a 30min recovery time, 0.2ml colcemid
(10mgml
 1) was added, and at 90min after irradiation, the
contents of the culture flasks were transferred to centrifuge tubes
and plunged into ice chippings. Subsequent centrifugation,
hypotonic treatment (0.075 M KCl) and fixation (methanol:glacial
acetic acid, 3:1) were carried out at 41C. Fixed cells were stored at
 201C overnight, or longer, prior to slide making.
Metaphase slides were made according to standard procedures
and stained with Giemsa. Slides from the family samples together
with those from the transport and internal assay control samples
were further coded prior to cytogenetic analysis. The eight
additional WRI control samples were analysed in conjunction
with another ongoing study according to the same criteria. For
each irradiated and unirradiated sample, 100 well-spread meta-
phases were analysed. Chromatid-type aberrations were scored
according to previously outlined criteria (Smart et al, 2003), with
breaks being defined as misaligned discontinuities and gaps as
single aligned discontinuities wider than the width of a chromatid.
For each irradiated sample, the total number of chromatid gaps
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sand breaks was determined and the spontaneous aberration yield
subtracted to give the induced G2 aberration yield. Two scorers
were used to eliminate scorer bias, with each scorer analysing 50
metaphases per sample.
Statistical methods
The distributions of aberrations among metaphase cells were
analysed for approximation to the Poisson distribution and
standard errors were calculated taking into account overdispersion
as described previously (Smart et al, 2003). For the WRI control
group, repeat sampling had been undertaken on nine of the
previously reported 19 individuals (Smart et al, 2003), and for the
calculation of the group mean, individual means were used
together with single sample results of the remaining 10 and
additional eight new samples. The standard error for this group
was calculated adjusting for overdispersion plus the additional
intraindividual variation. Aberration frequencies were tested for
heterogeneity using the w
2 test. The nonparametric Mann–
Whitney U-test was used to compare median induced aberration
frequencies between controls and the other donor groups. The
90th percentile values for induced aberrations per 100 cells were
calculated for the WRI control group and the partner control
group and used as the cutoff points for determining the
proportions of radiosensitive individuals in the other groups.
Using the WRI control group value, Fisher’s exact tests were used
to compare the proportion of radiosensitive individuals in the WRI
control group with each of the three family groups. Similarly, using
the 90th percentile for the partner group, comparisons were made
with the cancer survivor group and the offspring group.
The segregation analysis was performed by using the Statistical
Analysis for Genetic Epidemiology software (SAGE, 2004). This
programme uses a regressive model, in which distribution of the
residuals from the genotype means follow multivariate normality
(after Box–Cox transformation). In constructing pedigree like-
lihood, the parent–offspring relationship is explained in the
transmission parameter (tg), which is the probability that a parent
of genotype g transmits allele A to his/her offspring. We
constructed different disease transmission models by constraining
tg: general model (0ptAA, tAB, tBBp1), Mendelian model
(0ptAA¼1, tAB¼0.5, tBB¼0) and sporadic model
(tAA¼tAB¼tBB). The Mendelian model was accepted when (1)
the general model did not show a significantly better fit to the data
than the Mendelian model and (2) the general model fitted
significantly better than the sporadic model. The Akaike informa-
tion criterion (AIC) (Akaike, 1974) was used to compare the
models. In addition to the sex covariate (0 for male, 1 for female),
residual correlations from the family members were also included
in the model such that residual polygenic effects can be tested
(0prpo, rssp1, where rpo is correlation between parent–offspring
pairs and rss is correlation between siblings). For the most
parsimonious model, the contribution of the genetic factor to the
total phenotypic variance was computed from the ratio of genetic
variance (i.e., variability of genotypic means across the putative
genotypes) to the total phenotypic variance (an indicator of the
heritability of radiosensitivity, attributed to the putative genetic
factor inferred by the segregation analysis).
RESULTS
The radiation-induced G2 aberration frequencies for the transport
and internal assay controls are shown in Table 1. Analysis of the
transport samples indicated a significant intraindividual variation
in induced aberration yields (w
2
8¼24.06, P¼0.002). The Danish
volunteer who provided these samples became pregnant during the
course of the study and was pregnant at sample shipments 6–10.
Analysis of the samples provided prepregnancy (shipments 1–5)
revealed no significant intraindividual variation (w
2
4¼6.70,
P¼0.153) and a mean induced aberration frequency of
81.0073.17 per 100 cells, while for those provided during
pregnancy, there was a statistically significant difference
(w
2
3¼14.39, P¼0.002) and a mean induced aberration frequency
of 95.5076.71 per 100 cells. No significant difference was found
between the induced aberration frequencies for the samples
provided by the internal assay control (w
2
5¼5.91, P¼0.315), thus
indicating that there was no intrinsic assay effect.
Details of the cancer survivors together with individual
radiation-induced G2 aberration frequencies for all family
members are given in Table 2. Group information on the donor
characteristics and the induced aberration frequencies for the WRI
controls, partner controls, cancer survivors and the offspring are
provided in Table 3. Standardisation of the G2 assay had previously
been established using 57 blood samples from 19 healthy WRI
adult volunteers (Smart et al, 2003). The addition of eight samples
from new recruits to this group did not significantly affect
previous findings. Intraindividual variation was not significant for
seven out of nine volunteers (with one of the two that were
significant being border-line) and interindividual variation among
all 27 individuals remained highly statistically significant
(w
2
26¼60.05, Po0.001). Comparison of the median induced
aberration frequencies revealed no significant difference between
the WRI control and partner control groups, but significant
differences were observed when the WRI control group was
compared to the cancer survivor group (P¼0.009) or the offspring
group (P¼0.001). Although the mean values for the partner
control group and the cancer survivor group were similar, that for
the offspring group was higher (Table 3), this being mainly driven
by one high induced yield of 404 aberrations per 100 cells.
Confirmation of this unusually high value was obtained by
analysing the second irradiated blood sample and a check was
made on other samples irradiated at the same time in order to rule
out any error in the irradiation procedure.
Distributions of aberration frequencies for the WRI control and
three family groups are illustrated in Figure 1. Using the 90th
percentile cutoff point for the WRI control group of 122
aberrations per 100 cells for a radiosensitive/non-radiosensitive
response, the proportion of individuals with elevated G2 radio-
Table 1 Characteristics of transport and internal assay control donors and G2 induced aberration frequencies
Induced aberration frequencies per 100 cells at sampling shipments
Donor Sex
Age at first
sampling (years) 1 2 3 4 5 6 7 8 9 10
Mean aberration
frequency7s.e.
per 100 cells
Transport control F 37 91 58 87 97 72 98 117 — 110 57 87.4472.37
Internal assay control F 37 91 91 — — — 109 117 — 109 128 107.5072.43
s.e.¼standard error; F¼female; —¼data not available.
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ssensitivity was 11, 35, 52 and 53% for the WRI control, partner
control, cancer survivor and the offspring groups, respectively.
While the difference between the WRI control group and the
partner control group did not reach statistical significance
(P¼0.084), significant differences were found between the WRI
control group and the cancer survivor group (P¼0.002) and the
WRI control group and the offspring group (Po0.001). However,
when the 90th percentile value of 160 aberrations per 100 cells for
the partner control group was used as the cutoff point for
increased radiosensitivity, 13, 4 and 18% of the partner control,
cancer survivor and offspring groups, respectively, were classified
radiosensitive, while no individual from the WRI control group
Table 2 Characteristics of childhood and adolescent cancer survivors, their partners and offspring, with G2 induced aberration frequencies
Survivor Partner Offspring
a
Gender Primary cancer
Age at the
time of
treatment
(years)
Age at the
time of
sampling
(years)
Aberrations
in 100 cells
Age at the
time of
sampling
(years)
Aberrations
in 100 cells
Age at the
time of
sampling
(years)
Aberrations
in 100 cells
T01 F Hodgkin’s disease 15 35 122 28 84 2 89
7mths 146
T02 F Hodgkin’s disease 11 34 125 31 85 3 135
18 0
T03 M Rhabdomyosarcoma 9 34 103 32 115 8 91
5 108
T04 F Hodgkin’s disease 15 36 98 39 162 3 87
Thyroid cancer
b 30
T05 M Hodgkin’s disease 10 36 73 31 153 9 123
7 139
T06 F Teratoma 1mth 33 160 36 114 14 162
9 156
6 404
T07 F Hodgkin’s disease 19 29 109 30 100 2 105
T08 M Neuroblastoma 7mths 32 134 33 105 2 163
T09 M Wilms’ tumour 7 33 130 36 112 4 88
39 7
1 113
T10 F Wilms’ tumour 4 25 80 26 86 3 114
T12 F Hodgkin’s disease 14 25 128 31 115 11mths 73
T13 F Lymphoepithelioma 20 30 124 36 100 4mths 93
T15 M Pineocytoma 19 35 98 33 154 7 128
T19 M Hodgkin’s disease 17 35 76 35 132 12 150
10 96
T20 F Hodgkin’s disease 17 33 146 33 94 3 148
3 115
T21 F Hodgkin’s disease 19 35 90 37 166 9 151
T22 M Wilms’ tumour 1 31 130 36 88 2 108
T23 M Wilms’ tumour 5 32 145 36 101 6 163
1 140
T24 F Lymphoblastic lymphoma 14 36 154 37 141 13 124
Breast cancer
b 33 9 146
T25 F Neuroblastoma 1 36 129 37 189 9 159
T26 F Hodgkin’s disease 19 37 120 43 131 13 160
10 161
T27 F Wilms’ tumour 2 36 104 40 100 7 102
57 6
T28 F Wilms’ tumour 2 34 121 35 79 3 120
3 163
F¼female; M¼male; mths¼months.
aOffspring in birth order.
bSecondary cancers.
Table 3 Characteristics of WRI control, partner control, cancer survivor and offspring groups, with median and mean G2 induced aberration frequencies
Group
Number of
individuals
Male/
female
Median age
in years (range)
Median aberration
frequency per
100 cells (range)
Mean aberration
frequency7s.e.
per 100 cells
WRI controls 27 11/16 30 (20–54) 95.43 (59–154) 100.3973.28
Partner controls 23 15/8 35 (26–43) 112.00 (79–189) 117.6573.00
Cancer survivors 23 8/15 34 (25–37) 122.00 (73–160) 117.3572.95
Offspring 38 22/16 4.5 (4mths–14) 123.50 (73–404) 130.9572.30
WRI¼Westlakes Research Institute; s.e.¼standard error; mths¼months.
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sdisplayed enhanced radiosensitivity. Using the partner control
group to define the radiosensitivity cutoff point resulted in no
significant differences in the proportion of sensitive individuals
between the partner control group and either the cancer survivor
group (P¼0.608) or the offspring group (P¼0.729).
Heritability of the radiosensitivity phenotype was examined by
segregation analysis (Table 4). The offspring with the high value of
404 aberrations per 100 cells was not included in this analysis.
Compared to the general transmission model, the Mendelian
model was not rejected (w
2
3¼1.74, P¼0.628). The sporadic model
with equal transmission probability was rejected by the likelihood
ratio test (w
2
3¼11.6, P¼0.009). In addition, the Mendelian model
showed a smaller AIC value than either the general or the sporadic
model. Therefore, the Mendelian model was accepted over the
other two models. We further compared the autosomal dominant
model with the additive model. Based on the AIC criterion, the
autosomal dominant model provided a better fit with a smaller
AIC value (779.46). Neither gender covariate (P¼0.497) nor
residual familial correlation (converged into zero) turned out to
provide significant effects.
The most parsimonious model (last column of Table 4)
predicted from this analysis suggests a major gene locus at which
the dominant allele (labelled as A) confers a genotypic mean
induced frequency of 143.53 aberrations per 100 cells (same for AA
and AB genotypes), with the recessive homozygotes (BB) having a
mean of 97.82 induced aberrations per 100 cells. With frequencies
of 0.450 and 0.550, for the dominant and recessive phenotypes,
respectively (shown in the top panel of Table 4), the genetic
variance attributable to this putative locus becomes 517.13, with
residual variance within each genotype being 250.94 (shown in
Table 4). Thus, the estimate of the variance of chromosomal
radiosensitivity attributable to the putative dominant major gene
locus becomes: 513.13/(513.13þ250.94)¼0.673, suggesting that
more than two-thirds of the phenotypic variance of chromosomal
radiosensitivity is attributable to a putative major gene locus (with
dominant effect). This heritability estimate is also consistent with
an alternative prediction from a variance component analysis of
the data of the 23 nuclear families, performed by the SOLAR
software (Almasy and Blangero, 1998). For the unadjusted induced
G2 aberration frequency, the heritability estimate by this variance
component method was 0.60770.215 (significantly different from
zero, P¼0.006), which is not substantially different from the value
of 0.670 predicted from the parameter estimates of the model
fitting from SAGE.
DISCUSSION
The G2 chromosomal radiosensitivity assay requires stringent
technical conditions if reproducible results are to be obtained
(Scott et al, 1996; Bryant et al, 2002). Assay reproducibility has
been previously demonstrated in our laboratory (Smart et al, 2003)
and this had been confirmed in the present study by the analysis of
sequential samples from the internal assay control (Table 1).
Problems with reproducibility of results associated with storage
conditions and transportation of blood samples from distant
sources have been reported (Scott et al, 1999), although
reproducibility has been shown not to be an issue for samples
transported over short distances (Roberts et al, 1999; Smart et al,
2003). In order to minimise any potential effect of transportation,
samples were sent to WRI from Denmark in secondary packaging
(consisting of a screw-cap polyethylene tube to prevent breakage
and contain any spillage), at ambient temperature by road and by
air and in the possession of a personal courier at all times. Hence,
they were not subjected to any significant temperature fluctua-
tions, a factor that has been suggested as a possible cause of
intraindividual variability (Bryant et al, 2002). In addition, any
potential variation associated with transport was monitored by the
inclusion of a sample from a Danish control with each shipment.
While the first five samples provided by the Danish control gave
no indication of intraindividual variability, which could have been
associated with transportation, the final four samples gave variable
results (Table 1). However, since the volunteer was pregnant when
the last four samples were taken, this variability could be
associated with the accompanying hormonal changes. Support
for this view comes from in vitro studies, which indicate that
female reproductive hormones can influence radiation-induced
yields of chromosome aberrations (Roberts et al, 1997; Ricoul et al,
1998), and in vivo studies in mice (Ricoul and Dutrillaux, 1991)
and humans (Ricoul et al, 1997), which report fluctuating
radiation-induced chromosome aberration frequencies throughout
pregnancy.
Consideration of the three family groups, that is, cancer
survivors, their partners and their offspring, revealed no statistical
differences in the chromosomal radiosensitivity profiles between
the groups (Table 3, Figure 1), and thus, based on the family
comparisons, we have not been able to demonstrate an association
between increased G2 chromosomal radiosensitivity and predis-
position to childhood or adolescent cancer. However, when
comparisons were made with the WRI control group of healthy
volunteers, a clear distinction in radiosensitivity profile is
observed for both the cancer survivors and their offspring (Table 3,
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Figure 1 Distributions of G2 induced aberration frequencies in four
groups of donors. The dotted and solid vertical lines represent the cutoff
points for a normal and radiosensitive response, based on the 90th
percentile of the WRI control and partner control groups, respectively.
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sFigure 1). Using the 90th percentile cutoff for the WRI controls as
a measure of enhanced radiosensitivity suggests that 52% of the
cancer survivors and 53% of their offspring are exhibiting
enhanced sensitivity compared with 11% of the WRI controls.
On this basis, our results would seem to confirm previous work on
childhood cancer patients (Baria et al, 2002). This raises questions
as to the suitability of the partners of the cancer survivors to form
an appropriate control group. Although no significant differences
in either the medians or the percentage of individuals classed as
radiosensitive were found between the WRI control and the
partner control groups, when using the 90th percentile cutoff for
the WRI controls as a measure of enhanced radiosensitivity, 35%
of the partner control group were classed as radiosensitive.
Although a transportation effect cannot be ruled out for the
enhanced radiosensitivity profiles seen in all three family groups, it
is possible that the partners form a distinct group with heightened
radiosensitivity. A check of patient and partner questionnaires and
cancer registries confirmed that none of the partners had suffered
from cancer. However, cancer survivors may be more likely to
attract partners with some knowledge of cancer because the
partners have experienced it within their own families. Thus, the
partner control group may comprise a greater proportion of
individuals with cancer predisposition than a control group taken
randomly from a healthy population.
One of the offspring had an unusually high value of 404 induced
aberrations per 100 cells. To our knowledge, this is substantially
greater than any previously reported value for the G2 assay using
similar techniques. The child was aged 6 years at the time of
sampling and is healthy with no history of cancer.
Hodgkin’s disease and Wilms’ tumour form the two major
disease groups in our study (Table 2). Of the 10 cases of Hodgkin’s
disease, four exhibited evidence of enhanced radiosensitivity with
aberration levels at or above the cutoff point defined by the WRI
controls. Similar results were reported by Baria et al (2002), who
found that three out of six individuals with Hodgkin’s disease
displayed enhanced radiosensitivity. Three of the six cases of
Wilms’ tumour also displayed enhanced radiosensitivity. All six
cases were unilateral and for none of them was there any recorded
family history of Wilms’ tumour.
Studies of families of patients with breast cancer have provided
evidence for the G2 chromosomal radiosensitivity phenotype being
heritable, since first-degree relatives of patients demonstrating
enhanced sensitivity were more likely to be radiosensitive than
comparable healthy controls (Roberts et al, 1999; Scott, 2000).
Segregation analysis of family members suggested that 82% of the
variability in G2 radiosensitivity could be accounted for by a model
with a single major gene with two alleles combining in an additive
manner to give three phenotypes (Roberts et al, 1999, Scott, 2000).
However, although this model explained the majority of the
patterns of segregation observed in the breast cancer families,
there were a few families for which the inclusion of a second bi-
allelic gene gave a better fit to the data.
Our segregation analysis results are different in two respects.
Firstly, we found that the one-locus model is most parsimonious
(i.e., a second locus is not needed), with alleles having a
dominant–recessive relationship with regard to the effect on the
induced G2 aberration yield. Secondly, the contribution of this
locus to the total variance of the G2 aberration yield in our data
appears to be lower than that estimated by Roberts et al (1999).
Owing to the limited sample sizes, these differences may not be
real, but some methodological differences between the two studies
can be recognised. Firstly, unlike our sample of nuclear families,
which were not preselected based on G2 radiosensitivity, per se,
Roberts et al (1999) include in their analyses families with index
cases who showed either most sensitivity or had modal values of
G2 radiosensitivity. Even though these authors controlled for this
ascertainment bias in their pedigree analysis, their single selection
method of ascertainment correction may not be adequate (Ewens,
1991). Any unaccounted ascertainment bias due to enrichment by
extremely G2-sensitive individuals would influence the heritability
estimate in an upward direction, and this could account for the
difference between their value of 82% and our value of 67% for the
proportion of the variance attributed to the putative major gene.
Secondly, based on the distribution of G2 radiosensitivity of all
nonindex cases, Roberts et al (1999) used a log-transformation of
their original measurements prior to a segregation analysis. In
contrast, our unselected families provide a good fit to normality
(by a Q–Q plot analysis, data not shown), needing no transforma-
Table 4 Model parameters from segregation analysis of G2 radiosensitivity in 23 nuclear families of survivors of childhood cancer patients
Models analysed
Parameter General Equal s (sporadic) Mendelian Autosomal dominant Most parsimonious
qA 0.253 0.608 0.280 0.260 0.258
cAA 0.064
a 0.369
a 0.079
a 0.067
a 0.067
a
cAB 0.378
a 0.477
a 0.403
a 0.385
a 0.383
a
cBB 0.559
a 0.154
a 0.518
a 0.548
a 0.550
a
tAA 1.000
b 0.608 1.000
b 1.000
b 1.000
b
tAB 0.666 0.608
a 0.500
b 0.500
b 0.500
b
tBB 0.000
b 0.608
a 0.000
b 0.000
b 0.000
b
bAA 156.63 148.71 156.29 143.16 143.53
bAB 140.41 107.89 139.51 143.16
a 143.53
a
bBB 97.52 84.39 96.63 97.74 97.82
Residual variance 237.84 153.88 226.92 249.41 250.94
Major gene heritability (h
2) — — — — 0.673
l (Box–Cox parameter) 0.55 0.09 0.49 0.46 0.55
Residual rpo¼rss [0.000] [0.000] [0.000] [0.000] —
Gender cov 2.79 7.26 2.74 3.10 —
Number of parameters 9 8 8 7 5
 2lnL 765.02 776.23 766.37 767.46 767.92
AIC 783.02 792.23 782.37 781.46 777.92
P-value 0.001
c 0.245
c 0.296
d 0.794
e
qA¼frequency of disease allele; c¼genotype frequencies; t¼transmission probability of allele A; b¼genotype dependent mean; AIC¼Akaike information criterion;
rpo¼correlation between parent–offspring pairs; rss¼correlation between siblings. Values in brackets indicate that the estimate reached its boundary.
aDependent parameter.
bParameter is fixed to the shown value.
cLikelihood ratio test compared with the general model.
dCompared with the Mendelian model.
eCompared with the autosomal
dominant model.
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(Table 4) was simply to account for comingling of putative
differences of three genotype-specific mean values. In contrast, as
shown by Hanis and Chakraborty (1984) and Chakraborty and
Hanis (1987), when families are preselected based on nonrandom
trait values of probands, exclusion of probands alone does not
totally account for the bias of distributional properties, and hence,
the log-transformation may be another reason for the observed
differences of the segregation analyses inference. Thirdly, Roberts
et al (1999) used the software PAP, and we used SAGE for
conducting our analyses, and these two differ with regard to the
numerical approximations of likelihood evaluation under the mixed
model (i.e., major gene in addition to possible polygenes and
environmental effects). Finally, families included in the earlier study
had index cases, all of whom had breast cancer, while our index
cases (survivors of childhood and adolescent cancer receiving
radiation therapy) include a variety of cancers (Table 2). In addition,
their suggestion of a putative second locus effect is contingent upon
distribution of induced G2 aberration yields in offspring of very
discordant pairs of spouses, in which the ascertainment bias issue
would have been more complex. However, after consideration of
these differences and ignoring the finer details, there is agreement
between the two studies on the involvement of a single major gene
locus, which accounts for over two-thirds of the variation of G2
sensitivity, and our study is supportive of genetic heritability of
radiosensitivity in families of unselected cancer cases.
In conclusion, with respect to an association between cancer
susceptibility and chromosomal radiosensitivity, this study pro-
vides inconclusive but intriguing results. It is perhaps worth
noting that if reliance had been placed solely on the in-house WRI
controls for comparison with the cancer survivors and their
offspring, then confirmation of an association between G2 radio-
sensitivity and cancer susceptibility would not be in doubt.
However, choosing to study G2 radiosensitivity in the partners of
the cancer survivors, and finding that this group was statistically
indistinguishable from the cancer survivor and offspring
groups, has resulted in doubts as to the relevance of the assay as
a measure of predisposition to cancer. Nevertheless, this study has
provided evidence of heritability of the radiosensitivity phenotype.
Future studies will expand all three family groups and also
investigate further whether a transport factor could be influencing
the results.
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